Celltrion Inc., a South Korean biopharmaceutical company, announced in a regulatory filing that its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly for $330 million. The transaction was disclosed on Tuesday, September 23, 2025.
Imclone Systems LLC is a U.S. production facility that was previously owned by Lilly. The sale represents a divestiture of manufacturing assets by Lilly, potentially reducing its domestic production capacity.
The $330 million transaction provides Lilly with a significant cash inflow and allows the company to streamline its manufacturing portfolio. For Celltrion, the acquisition expands its U.S. manufacturing footprint and supports its growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.